Abstract: An exhaust gas treating an apparatus and a vehicle vehicles equipped with the apparatus, wherein a liquid-including substance having salt including oxygen acid radical of nitrogen is installed in an exhaust gas passage to treat exhaust gas having carbon-containing particles and nitrogen oxides for removal of these harmful components.

Abstract: An apparatus and a vehicle equipped with the apparatus for preventing slip and keeping a good running on the ground including a road covered with frozen water such as ice and/or snow by cooling a wheel surface of the vehicle and/or a ground surface just in front of a point where the wheel comes into contact therewith by using cold air directly produced by expansion of compressed air in the running of the vehicle in response to change in the vehicle driving condition and further, dealing with a hydroplaning of the wheel on a wet ground surface at not freezing seasons by injection of the compressed air.

Abstract: A protein having human plasmin inhibiting activity, substantially equivalent reactivity with human plasmin to a human .alpha..sub.2 -plasmin inhibitor derived from plasma, a binding ability to human fibrin about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, and a molecular weight of about 50,000 to about 77,000.

Abstract: This invention provides a monoclonal antibody or its fragment specific to a human .alpha..sub.2 -plasmin inhibitor, said antibody having the function of specifically blocking that site of the human .alpha..sub.2 -plasmin inhibitor which inhibits the fibrinolytic activity of plasmin, and of suppressing said fibrinolytic activity inhibiting function of said .alpha..sub.2 -plasmin inhibitor, and also a hybridoma capable of producing the monoclonal antibody. Said monoclonal antibody or its fragment is useful for the immunological determination of a human .alpha..sub.2 -plasmin inhibitor, the separation or recovery of a human .alpha..sub.2 -plasmin inhibitor from a liquid containing the human .alpha..sub.2 -plasmin inhibitor, and the treatment of a thrombotic disease.

Abstract: A protein having human plasmin inhibiting activity, substantially equivalent reactivity with human plasmin to a human .alpha..sub.2 -plasmin inhibitor derived from plasma, a binding ability to human fibrin about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, and a molecular weight of about 50,000 to about 77,000.

Abstract: In methods for immunologically assaying free lipoprotein associated coagulation inhibitor (hereafter abbreviated as "LACI") in a human inspection sample using a first antibody immobilized on an insoluble carrier and a labeled second antibody, a method for immunological assay of free LACI and a kit therefor wherein(i) any one antibody of the first antibody and the second antibody is a monoclonal antibody recognizing the polypeptide (K3) of the following amino sequence ##STR1## (hereafter referred to as a "K3-antibody"), and (ii) the other antibody is a monoclonal antibody recognizing the polypeptide (K1) of the following amino acid sequence ##STR2## (hereafter referred to as a "K1-antibody").

Abstract: This invention relates to a novel physiologically active polypeptide containing modified amino acids on both terminals at the amino-terminus and the carboxy-terminus in the amino acid sequence of the human tumor neclosis factor (human TNF), a recombinant plasmid containing a DNA region encoding the polypeptide, a recombinant microorganism cell transformed with the recombinant plasmid, a method of producing the polypeptide by cultivating the microorganism cell, a pharmaceutical composition containing the polypeptide and a method of purifying and recovering the polypeptide. The polypeptide in this invention has excellent antitumor activity compared to the human TNF and can be utilized as an active ingredient of a pharmaceutical composition having antitumor activity.

Abstract: cDNA encoding a human .alpha..sub.2 -plasmin inhibitor precursor protein represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; an amino acid sequence of a human .alpha..sub.2 -plasmin inhibitor precursor represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; and genomic DNA encoding a human .alpha..sub.2 -plasmin inhibitor protein which is composed of exons II, III, IV, V, VI, VII, VIII, IX and X in FIG. 4 of the accompanying drawings, said exons being bonded to one another via introns.

Abstract: A method of immunologically determining free human protein S in an assay sample, which comprises contacting a primary antibody fixed to an insoluble solid carrier and a labelled secondary antibody with the assay sample, the primary and secondary antibodies having the property of binding to different epitopes of free human protein S, and one of the primary and secondary antibodies being a monoclonal antibody having the property of not binding to a complex of the human protein S and human complement cofactor C4b-binding protein (C4bp) but specifically binding to the free human protein S.

Abstract: A method of cultivating animal or plant cells, which consists essentially of contacting a cultivation liquor having animal or plant cells suspended therein with a liquid fluorocarbon having molecular oxygen dissolved therein, characterized in that said cultivation liquor forms a continuous suspension phase which has cell densities of at least 4.times.10.sup.6 cells/ml, that said contact is made by feeding said liquid fluorocarbon into the cultivation liquor from above the cultivation liquor such that 1 ml of liquid fluorocarbon has a surface area of about 6 to about 300 cm.sup.2 whereby the liquid fluorocarbon falls downward through the cultivation liquor by gravity, and that said cultivation liquor has a volume of at least about 10 liters.

Abstract: The present invention provides an enhancer DNA segment, a gene fragment having (a) the enhancer DNA segment and (b) a structural gene such as human D, V and J gene, and a promoter. A hybrid DNA (1) having a phage DNA fragment from Charon 4A phage vector and human DNA fragments, a Charon 4A phage containing the hybrid DNA (1), a hybrid DNA (2) having a PBR322 fragment and human DNA fragment, a transformant of E. coli C600 strain transformed with the hybrid DNA (2), plasmid pSV2-H1G1 obtained by inserting a human DNA fragment into a vector pSV-2gpt, a transformant of E. coli MC 1000 strain transformed with the plasmid pSV2-H1G1 and a transformant of mouse myeloma cells J558L or NS-1 transformed with the plasmid pSV2-H1G1 are also provided.

Abstract: A method of confirming the diagnosis of Kawasaki disease in a patient which comprises assaying the patient's body fluid for the presence of elevated levels of a substance specifically bound by an anti-tumor necrosis factor monoclonal antibody.

Abstract: A novel physiologically active polypeptide having antitumor activity obtained by improving human tumor necrosis factor (TNF). The amino acid sequence of the polypeptide essentially corresponds to that of human tumor necrosis factor, except that ten amino acids Nos. 1 to 10 are deleted and (Met).sub.n -Arg-Lys-Arg are added to the amino (NH.sub.2)-terminus, where n is 0 or 1. Other amino acid modifications can also be made to the polypeptide while retaining high antitumor activity. The novel polypeptide has less side effects that the natural-type TNF, particularly with respect to cytotoxicity. A a DNA fragment encoding the polypeptide, a recombinant plasmid containing the DNA fragment, a recombinant microorganism cell transformed with the plasmid, a method of producing a novel physiologically active polypeptide using the microorganism cell, and a pharmaceutical composition comprising the polypeptide as an active ingredient are also provided.

Abstract: A mouse-human chimaeric immunoglobulin heavy chain comprising (a) the amino acid sequence of a mouse immunoglobulin heavy chain variable region and (b) the amino acid sequence of a human immunoglobulin heavy chain constant region and reacting specifically with human common acute lympohocytic leukemia antigen and a chimaeric DNA fragment which encodes the amino acid sequence of the above mouse-human chimaeric immunoglobulin heavy chain.

Abstract: A plant metabolism regulating agent comprising as an active ingredient an alpha,beta or beta,gamma-un-saturated carboxylic acid or its derivative. It is useful for controlling the metabolism of a plant, facilitating the growth of a beneficial plant such as cereals by inhibiting the growth of undesirable plants or eradicating them, regulating the growth of a plant and dwarfing a plant.

Abstract: A monoclonal antibody which is specific to human protein C which has calcium bound at the gammacarboxyglutamic acid(Gla) domain and does not recognize human protein C which is not bound to calcium at the Gla domain. The monoclonal antibody is used in an immunoassay method for determining human protein C having a Gla domain and in a method for recovering human protein C having a Gal domain.

Abstract: Double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.67 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 1 of the accompanying drawings; and double-stranded DNA characterized by having sequences complementary to a single-stranded DNA which has a molecular size of about 2.70 Kb and is derived from mungbean yellow mosaic virus, and giving the restriction endonuclease cleavage map shown in FIG. 2 of the accompanying drawings; and hybrid DNAs having the double-stranded DNAs inserted thereinto.

Abstract: A plant growth promoter comprising as an active ingredient for plant growth promotion at least one phenylglycine selected from the group consisting of(1) monomeric phenylglycines,(2) N-phenylglycylphenylglycines, and(3) cyclic dimers of phenylglycines.

Abstract: A novel phenoxycarboxylic acid of formula (I) is disclosed. The compound is effective as herbicide for eradicating broad-leaved weeds. A combination of the phenoxycarboxylic acid and a N-phosphonomethylglycine or a glufosinate which is known as a herbicide is very effective for eradicating both broad-leaved weeds and narrow-leaved weeds.

Abstract: A method of separating activated human protein C, which comprises bringing a mixture containing activated human protein C having a gamma-carboxyglutamic acid (Gla) domain in the presence of a calcium ion into contact with a fixed antibody comprising an insoluble carrier and fixed thereto an antibody to a complex of human protein C and a calcium ion bound to the Gla domain whereby the activated human protein C is captured by the fixed antibody in the form in which the calcium ion is bound to the Gla domain.